 |
MYELOMA
CANADA NEWS
August 2016
Spotl
ight on
RESEARCH
|
SPOTLIGHT ON RESEARCH
ONE OF THE FOUR STRATEGIC PILLARS OF
MYELOMA CANADA
|
Founded in 2005 by two myeloma patients, Myeloma Canada is the only national non-profit organization uniquely devoted to the Canadian myeloma community. Myeloma Canada's patient-focused priorities are driven by its four strategic pillars:
awareness, education, advocacy and
research. Our research pillar, as defined by
promoting clinical research and access to new drug trials in Canada, has taken major strides forward over the past few years, having developed a strong coast-to-coast network devoted to improving outcomes for all patients across Canada.
Over the past 15 years, innovative research has led to the development of new treatments that have increased the median life expectancy of a myeloma patient to 8-10 years or longer, transforming this 'incurable disease' to a 'highly treatable disease'. Although there is no known cure for myeloma at this point in time, huge strides have been made in the evolution of treatment options that are continually improving, moving us closer to not just increasing life expectancy overall, but to a future where myeloma is no longer a fatal disease.
Committed to fuelling the momentum in new research and innovation, while keeping in mind our main priority - the patient - Myeloma Canada has revolutionized the research and treatment landscape in Canada with the creation of the
Myeloma Canada Research Network (MCRN) and the
MCRN National Myeloma Database.
Click on the article links below to learn more about the MCRN.
|
THE MYELOMA CANADA RESEARCH NETWORK (MCRN):
BRINGING MADE-IN-CANADA TRIALS TO CANADIAN PATIENTS
From its early beginnings in 2010, the Myeloma Canada Rese
arch Network (MCRN) has evolved into an internationally recognized and respected co
llaborativ
e clinical trial research program. This past January, the MCRN officially became a distinct
entity in partnership with Myeloma Canada to enable a more effective development and operationalization of clinical trials. The MCRN, a rarity for a patient organization, demonstrates Myeloma Canada's commitment to patient-focused clinical research. Through its unique coast-to-coast network of world-class researchers, the MCRN promotes the collaboration and sharing of scientific data and expertise, while bringing more clinical trials, to more patients in more centres across Canada.
|
HOW DO ALL CANADIAN PATIENTS BENEFIT FROM THE MCRN?
Whether participating in an MCRN clinical trial or not,
ALL Canadian patients will benefit from the research program.
|
|
MEET THE EXPERT: ENGIN GUL
DIRECTOR OF CLINICAL RESEARCH OPERATIONS, M
CRN
As part of the Leadership Team, Engin participates
in the development and implementation of organizatio
nal strategies and best practices that ensure superior research conduct and strategic growth of the Myeloma Canada Rese
arch Network (MCRN). Learn more about Engin's role with the MCRN and how clinical trials work in a personal interview by clicking here.
|
|
IN CONVERSATION WITH ALDO DEL COL
CO-FOUNDER AND CHAIRMAN
MYELOMA CANADA AND
THE MYELOMA CANADA RESEARCH NETWORK
Over the past eleven years, Aldo has directed his attention to building an effective national platform to address the
needs of the Canadian myeloma community.
More recently, his focus
has been on advancing Canadian myeloma research by working closely with Canada's leading myeloma experts to establish the Myeloma Canada Research Network (MCRN) to drive patient-focused research and optimize clinical outcomes. Learn more about Aldo's vision and how is all began by clicking here.
|
MYELOMA CANADA AND CANCER RESEARCH SOCIETY AWARD $120,000 TO ALBERTA RESEARCHER
Myeloma
Canada, in partnership with the Cancer Research Society, is pleased to announce that Dr. Don Morris, Associate Professor at University of Calgary and Director of the Tom Baker Cancer Centre Translational Laboratory, is the recipient of the third jointly-funded Myeloma Canada/Cancer Research Society Operating Grant for his project entitled "Next generation immune treatment strategies for multiple myeloma: immune modulators in conjunction with oncolytic viral therapy". The value of the grant is $120,000 over two years.
Congratulations Dr Morris!
|
THE 2016 MULTIPLE MYELOMA MARCH:
FUNDING CANADIAN RESEARCH AND INCREASING AWARENESS
Research and Advocacy are on the forefront of Myeloma Canada's projects this year. We're very pleased to announce that an important beneficiary of the 2016 Multiple Myeloma March is the MCRN. Furthermore, the funds will also aim to increase awareness, develop new educational programs and facilitate access to new treatment options and therapies in Canada.
|
|
See what's happening on the social sites of Myeloma Canada:
|
|
| |
|
|
|
|
